Trials / Completed
CompletedNCT04060719
A Study in Healthy Men to Test Whether Rifampicin Influences the Amount of BI 894416 in the Blood
Effect of Rifampicin on the Pharmacokinetics of a Single Oral Dose of BI 894416 in Healthy Male Subjects (an Open-label, One-way Crossover Study)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The main objective of this trial is to investigate the effect of rifampicin on the pharmacokinetics of BI 894416.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 894416 | tablet |
| DRUG | Rifampicin | tablet |
Timeline
- Start date
- 2019-09-04
- Primary completion
- 2019-10-17
- Completion
- 2019-10-17
- First posted
- 2019-08-19
- Last updated
- 2023-08-14
- Results posted
- 2023-08-14
Locations
1 site across 1 country: Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04060719. Inclusion in this directory is not an endorsement.